Lenalidomide is used to treat multiple myeloma through the interaction with the ubiquitin E3 ligase cereblon, which leads to the degradion of the Ikaros transcription factors IKZF1 and IKZF3. This indicates that the major action of lenalidomide is to re-target the activity of an enzyme rather than block the activity of an enzyme or signaling process.
Usually ships within 24 hours.